May 03, 2024, 10:41:46 AM IST FY24 proved to be an exceptional year for equity markets worldwide, with Indian equity markets exhibiting outstanding performance. Throughout the year, Indian equities consistently achieved new all-time highs, accompanied by continuous surges in market volumes. In April 2024, mid and smallcap indices rallied by 6% and 11% respectively while … Read more
Global brokerage Morgan Stanley maintained an overweight rating on Dalmia Bharat, Macquarie recommended an outperform rating on Axis Bank, Jefferies maintained a hold rating on Kotak Mahindra Bank and Investec has a buy rating on Aurobindo Pharma. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Morgan Stanley … Read more
Aurobindo Pharma, part of the pharma space, has rallied more than 100% in FY24 but found some resistance above Rs 1,100 levels in January 2024. The stock underwent price wise correction since January 2024 and is now showing signs of bottoming out which suggests that bulls are ready to take the charge again. Short-term traders … Read more
“Aurobindo, I think they have got into some issues with one of their major plants now. I was just listening to them saying that it will be resolved in two-three months,” says Sandip Sabharwal, asksandipsabharwal.com.Let us begin by talking some of these pharma names itself. If you track Aurobindo Pharma or Divi’s Lab closely, either … Read more
